Just out , reads well.OncoSil PanCO Clinical Trial Presented at...

Just out , reads well.

OncoSil PanCO Clinical Trial Presented at ESMO World Congress
on Gastrointestinal Cancer (WCGIC) focusing on resected and non-resected
participant data
Sydney, Australia, 29 June 2022: OncoSil Medical Limited (ASX: OSL) (OncoSil or the Company) is pleased
to announce that the Principal Investigator of the PanCO study will be presenting both an oral and poster
presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) on 29 June 2022. The
presentation is titled “Comparison of resected vs. non-resected patients with unresectable locally
advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or
FOLFIRINOX chemotherapy in the PanCO study”. The presentation focuses upon data in the resected
and non-resected participants in the PanCO Study. The presenter is Dr Paul Ross, Consultant Medical
Oncologist from Guy’s & St Thomas’ Hospital NHS Foundation Trust, London and Principal Investigator of
the PanCO study. The presentation and poster can be viewed after 2 July 2022 at
https://www.oncosil.com/news/.

OncoSil’s CEO and Managing Director, Mr Nigel Lange said:
“We are delighted to be able to present additional data from our PanCO Study, comparing the baseline
characteristics and outcomes in the participants who went on to have surgical resection compared to
those who did not. This new analysis shows that the resected participants had a substantial response to
treatment before they underwent surgery. These clinical findings have motivated increased interest from
Hepato-Pancreatico-Billary (HPB) surgeons who have been encouraged by the reduction in tumour
volumes following treatment. Reduction of tumour volume may increase the potential for surgical
resection and may be linked with the encouraging survival of the resected cohort of patients being
administered the OncoSilTM device.”

About WCGIC:
The ESMO World Congress on Gastrointestinal Cancer represents the year’s premier gathering of
international oncology professionals who are dedicated to improving the lives of patients impacted by
diseases of the GI tract. The Congress is the leading global platform for discussing the latest emerging
data and new research in this rapidly advancing scientific field. It is being held on 29 June 2022 to 2 July
2022 in Barcelona, Spain.